Global Leading Stem Cell Producer Cellcolabs Secures USD 12M to Drive Technical Development
STOCKHOLM,SWEDEN:
Cellcolabs, the Swedish biotech transforming healthcare through industrial-scale production of high-quality stem cells, has secured USD 12 million in primary funding from Titian Capital, through its life-sciences platform, Titian Life Sciences.
The investment brings Cellcolabs’ total funding to USD 37 million and will support technical development and international expansion as the company advances its mission to make high-quality Mesenchymal Stem Cells (MSCs) more accessible and affordable for both research and therapeutic use.
Cellcolabs was founded in 2021 to democratise access to high-quality stem cells. Today, its Mesenchymal Stem Cells (MSCs) are used by university hospitals across the globe, as well as the world’s top athletes, celebrities, and Silicon Valley founders. The company is working toward reducing the cost of stem cells by 90% by 2035 and ensuring that access is no longer a limiting factor in scientific and therapeutic progress.
Dr. Mattias Bernow, CEO of Cellcolabs, comments: “The industry is reaching an inflection point. Scientific evidence is mounting. Regulatory pathways are opening. The demand for stem cells has never been greater. Yet scalable access remains the missing piece. The partnership with Titian Life Sciences provides Cellcolabs with both the capital and strategic footprint needed to grow internationally. Together, we are building the infrastructure that can make stem cell therapies widely available, not someday, but in our lifetime.”
Kayaan Unwalla, Managing Director of Titian Capital, adds:
“The field of regenerative medicine is entering a new era. Our investment in Cellcolabs reflects Titian Capital’s conviction that scalable, standardised production of GMP grade stem cells will be fundamental to the future of medicine. We are delighted to support Cellcolabs’ expansion and in doing so, we aim to accelerate the global accessibility of safe, high-quality cellular therapies and help translate cutting-edge science into transformative patient outcomes”
With growing global demand for clinical-grade stem cells, Cellcolabs’ large-scale, GMP-certified production represents a crucial step toward making regenerative treatments both commercially viable and scientifically robust. The company continues to broaden access to high-quality stem cells, supporting research, innovation, and clinical development worldwide.
About Cellcolabs
Cellcolabs is a Swedish biotech company that specialises in large-scale production of mesenchymal stem cells. Cellcolabs’ mission is to prevent and treat diseases by making high quality stem cells available and affordable through industrial scale production and collaborations. The MSCs produced at Cellcolabs follow a production protocol that has been developed at the Karolinska Institutet for over 20 years. Cellcolabs was founded in 2021 and is led by CEO Dr. Mattias Bernow. The company’s investors include Titian Capital, Norrsken Launcher and prominent angel investors.